$RLAY

Catinazzo Thomas sold $27K of RLAY

Catinazzo Thomas (Chief Financial Officer) sold 1,459 shares of Relay Therapeutics, Inc. (RLAY) at $18.61 on 2026-07-28.

Original reporting
SEC EDGAR · Catinazzo Thomas
Published Jul 30, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RLAY
Neutral
low confidence
Mentioned
$RLAY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYNeutralLow
01

Why it matters

The only new fact is the CFO’s open-market sale size, price, and post-transaction holdings; it does not include any accompanying company guidance or event.

02

Market read

Traders may note the insider sale for sentiment, but there is no fundamental catalyst in the text.

03

What to watch

The article lacks context on total holdings, prior sale history, and whether proceeds relate to taxes or diversification, limiting inference.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-30, transaction dated 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.

Company-level read

Ticker impact

$RLAYNeutralLow confidence
Context

Relay Therapeutics CFO Thomas Catinazzo sold 1,459 shares at $18.61 in an SEC Form 4 open-market sale.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted unless paired with other new company catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction, and the article provides no new operational, financial, or regulatory development beyond the sale details.

Market effects

No clear sector read-through from a single CFO open-market sale.

None indicated.

None indicated.

Counterpoint

Insider sales are often planned for diversification or tax needs, and the absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Relay Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Thomas Catinazzo

    Chief Financial Officer who reported the sale.

Related articles

$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 4 rlay-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patient

$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.